IDO1 and melanoma: In a cohort of melanoma patients receiving adjuvant treatment with IFN- α2b, levels Kyn/Trp levels, that is a biomarker of Ido-1 activation, were monitored under treatment and they resulted positively increased in plasma from treated patients as compared to untreated cohort [19].